Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study

Andrea Casadei‐Gardini; Margherita Rimini; Masatoshi Kudo; Shigeo Shimose; Toshifumi Tada; Goki Suda; Myung Ji Goh; André Jefremow; Mario Scartozzi; Giuseppe Cabibbo; Claudia Campani; Emiliano Tamburini; Francesco Tovoli; Kazuomi Ueshima; Tomoko Aoki; Hideki Iwamoto; Takuji Torimura; Takashi Kumada; Atsushi Hiraoka; Masanori Atsukawa; Ei Itobayashi; Hidenori Toyoda; Naoya Sakamoto; Takuya Sho; Wonseok Kang; Jürgen Siebler; Markus F. Neurath; Valentina Burgio; Stefano Cascinu

doi:10.1159/000525145

Related publications

Supplementary Material for: REal life study of LEnVAtiNib therapy for HepAtocellular carcinoma: RELEVANT study

Andrea Casadei‐Gardini, M. Rimini, Masatoshi Kudo, S. Shimose, Toshifumi Tada, Goki Suda, Goh M.J., André Jefremow, Mario Scartozzi, Giuseppe Cabibbo, Claudia Campani, Emiliano Tamburini, Francesco Tovoli, Kazuomi Ueshima, Tomoko Aoki, Hiroki Iwamoto, Takuji Torimura, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Ei Itobayashi, Hideki Toyoda, Naoya Sakamoto, Sho T., Wonseok Kang, Jürgen Siebler, Neurath M.F., V. Burgio, Stefano Cascinu

Article2023

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: A large, real-life, worldwide population.

Margherita Rimini, Andrea Casadei‐Gardini, Mara Persano, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Jaekyung Cheon, Fabian Finkelmeier, Lorenza Rimassa, José Presa, Gianluca Masi, Changhoon Yoo, Sara Lonardi, Francesco Tovoli, Mario Scartozzi, Valentina Burgio, Stefano Cascinu, Alessandro Cucchetti

Article2017

Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC).

Masafumi Ikeda, Kenji Ikeda, Masatoshi Kudo, Yukio Osaki, Takuji Okusaka, Toshiyuki Tamai, Takuya Suzuki, Takashi Hisai, Hideaki Miyagishi, Kiwamu Okita, Hiromitsu Kumada

Editorial Material2018

Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma

Masatoshi Kudo

Article2022

Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study.

Andrea Casadei‐Gardini, Margherita Rimini, Lorenza Rimassa, Valentina Burgio, Masatoshi Kudo, Toshifumi Tada, Shigeo Shimose, Goki Suda, Changhoon Yoo, Jaekyng Cheon, David J. Pinato, Mario Scartozzi, Stefano Cascinu